These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 26406139)

  • 1. Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease.
    Stephenson D; Hu MT; Romero K; Breen K; Burn D; Ben-Shlomo Y; Bhattaram A; Isaac M; Venuto C; Kubota K; Little MA; Friend S; Lovestone S; Morris HR; Grosset D; Sutherland M; Gallacher J; Williams-Gray C; Bain LJ; Avilés E; Marek K; Toga AW; Stark Y; Forrest Gordon M; Ford S
    J Parkinsons Dis; 2015; 5(3):581-94. PubMed ID: 26406139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease.
    Bloem BR; Marks WJ; Silva de Lima AL; Kuijf ML; van Laar T; Jacobs BPF; Verbeek MM; Helmich RC; van de Warrenburg BP; Evers LJW; intHout J; van de Zande T; Snyder TM; Kapur R; Meinders MJ
    BMC Neurol; 2019 Jul; 19(1):160. PubMed ID: 31315608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The project data sphere initiative: accelerating cancer research by sharing data.
    Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
    Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seeking progress in disease modification in Parkinson disease.
    Lungu C; Cedarbaum JM; Dawson TM; Dorsey ER; Faraco C; Federoff HJ; Fiske B; Fox R; Goldfine AM; Kieburtz K; Macklin EA; Matthews H; Rafaloff G; Saunders-Pullman R; Schor NF; Schwarzschild MA; Sieber BA; Simuni T; Surmeier DJ; Tamiz A; Werner MH; Wright CB; Wyse R
    Parkinsonism Relat Disord; 2021 Sep; 90():134-141. PubMed ID: 34561166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases.
    Stephenson D; Aviles E; Bain LJ; Brumfield M; Carrillo M; Comery TA; Compton C; Corrigan B; Gordon MF; Jack CR; Katz R; Logovinsky V; Satlin A; Marek K; Nicholas T; Polhamus D; Angersbach BS; Raghavan N; Romano G; Romero K; Shaw L; Woodcock J; Vradenburg G; Isaac M
    Ther Innov Regul Sci; 2013 Nov; 47(6):632-638. PubMed ID: 30235546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases.
    Romero K; de Mars M; Frank D; Anthony M; Neville J; Kirby L; Smith K; Woosley RL
    Clin Pharmacol Ther; 2009 Oct; 86(4):365-7. PubMed ID: 19763117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.
    Merchant KM; Cedarbaum JM; Brundin P; Dave KD; Eberling J; Espay AJ; Hutten SJ; Javidnia M; Luthman J; Maetzler W; Menalled L; Reimer AN; Stoessl AJ; Weiner DM;
    J Parkinsons Dis; 2019; 9(1):31-61. PubMed ID: 30400107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson's disease?
    Lenka A; Jankovic J
    Expert Rev Neurother; 2023 Feb; 23(2):107-122. PubMed ID: 36803618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective.
    Stephenson D; Badawy R; Mathur S; Tome M; Rochester L
    J Parkinsons Dis; 2021; 11(s1):S103-S109. PubMed ID: 33579873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Charting a path toward combination therapy for Alzheimer's disease.
    Stephenson D; Perry D; Bens C; Bain LJ; Berry D; Krams M; Sperling R; Dilts D; Luthman J; Hanna D; McKew J; Temple R; Fields FO; Salloway S; Katz R
    Expert Rev Neurother; 2015 Jan; 15(1):107-13. PubMed ID: 25540951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease modification in Parkinson's disease.
    Henchcliffe C; Severt WL
    Drugs Aging; 2011 Aug; 28(8):605-15. PubMed ID: 21812497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.
    Arnerić SP; Batrla-Utermann R; Beckett L; Bittner T; Blennow K; Carter L; Dean R; Engelborghs S; Genius J; Gordon MF; Hitchcock J; Kaplow J; Luthman J; Meibach R; Raunig D; Romero K; Samtani MN; Savage M; Shaw L; Stephenson D; Umek RM; Vanderstichele H; Willis B; Yule S
    J Alzheimers Dis; 2017; 55(1):19-35. PubMed ID: 27662307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prerequisites to launch neuroprotective trials in Parkinson's disease: an industry perspective.
    Streffer JR; Grachev ID; Fitzer-Attas C; Gomez-Mancilla B; Boroojerdi B; Bronzova J; Ostrowitzki S; Victor SJ; Fontoura P; Alexander R
    Mov Disord; 2012 Apr; 27(5):651-5. PubMed ID: 22508283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science.
    Stephenson D; Alexander R; Aggarwal V; Badawy R; Bain L; Bhatnagar R; Bloem BR; Boroojerdi B; Burton J; Cedarbaum JM; Cosman J; Dexter DT; Dockendorf M; Dorsey ER; Dowling AV; Evers LJW; Fisher K; Frasier M; Garcia-Gancedo L; Goldsack JC; Hill D; Hitchcock J; Hu MT; Lawton MP; Lee SJ; Lindemann M; Marek K; Mehrotra N; Meinders MJ; Minchik M; Oliva L; Romero K; Roussos G; Rubens R; Sadar S; Scheeren J; Sengoku E; Simuni T; Stebbins G; Taylor KI; Yang B; Zach N
    Digit Biomark; 2020; 4(Suppl 1):28-49. PubMed ID: 33442579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Building a roadmap for developing combination therapies for Alzheimer's disease.
    Perry D; Sperling R; Katz R; Berry D; Dilts D; Hanna D; Salloway S; Trojanowski JQ; Bountra C; Krams M; Luthman J; Potkin S; Gribkoff V; Temple R; Wang Y; Carrillo MC; Stephenson D; Snyder H; Liu E; Ware T; McKew J; Fields FO; Bain LJ; Bens C
    Expert Rev Neurother; 2015 Mar; 15(3):327-33. PubMed ID: 25708309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leveraging the regulatory framework to facilitate drug development in Parkinson's disease.
    Müller MLTM; Stephenson DT
    Handb Clin Neurol; 2023; 193():347-360. PubMed ID: 36803822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop.
    Stephenson D; Belfiore-Oshan R; Karten Y; Keavney J; Kwok DK; Martinez T; Montminy J; Müller MLTM; Romero K; Sivakumaran S
    Neurotherapeutics; 2023 Oct; 20(6):1682-1691. PubMed ID: 37823970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update.
    McFarthing K; Rafaloff G; Baptista M; Mursaleen L; Fuest R; Wyse RK; Stott SRW
    J Parkinsons Dis; 2022; 12(4):1073-1082. PubMed ID: 35527571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential therapeutic targets for Parkinson's disease.
    Stoessl J
    Expert Opin Ther Targets; 2008 Apr; 12(4):425-36. PubMed ID: 18348679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.